Heidelberg Pharma Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Andreas Pahl
Chief executive officer
€328.3k
Total compensation
CEO salary percentage | 73.1% |
CEO tenure | less than a year |
CEO ownership | n/a |
Management average tenure | 1.2yrs |
Board average tenure | 12yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Feb 29 2024 | n/a | n/a | -€18m |
Nov 30 2023 | n/a | n/a | -€20m |
Aug 31 2023 | n/a | n/a | -€22m |
May 31 2023 | n/a | n/a | -€27m |
Feb 28 2023 | n/a | n/a | -€19m |
Nov 30 2022 | €328k | €240k | -€20m |
Aug 31 2022 | n/a | n/a | -€21m |
May 31 2022 | n/a | n/a | -€22m |
Feb 28 2022 | n/a | n/a | -€27m |
Nov 30 2021 | €442k | €240k | -€26m |
Aug 31 2021 | n/a | n/a | -€25m |
May 31 2021 | n/a | n/a | -€22m |
Feb 28 2021 | n/a | n/a | -€20m |
Nov 30 2020 | €295k | €207k | -€18m |
Aug 31 2020 | n/a | n/a | -€17m |
May 31 2020 | n/a | n/a | -€15m |
Feb 29 2020 | n/a | n/a | -€12m |
Nov 30 2019 | €288k | €200k | -€10m |
Aug 31 2019 | n/a | n/a | -€10m |
May 31 2019 | n/a | n/a | -€11m |
Feb 28 2019 | n/a | n/a | -€12m |
Nov 30 2018 | €286k | €200k | -€12m |
Aug 31 2018 | n/a | n/a | -€11m |
May 31 2018 | n/a | n/a | -€11m |
Feb 28 2018 | n/a | n/a | -€11m |
Nov 30 2017 | €241k | €171k | -€11m |
Compensation vs Market: Andreas's total compensation ($USD353.40K) is about average for companies of similar size in the UK market ($USD348.42K).
Compensation vs Earnings: Andreas's compensation has been consistent with company performance over the past year.
CEO
Andreas Pahl
less than a year
Tenure
€328,276
Compensation
Prof. Dr. Andreas Pahl is Chief Executive Officer & Spokesman of the Executive Board at Heidelberg Pharma AG since February 1, 2024 and had been its Chief Scientific Officer and Member of the Executive Man...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Spokesman of the Executive Board | less than a year | €328.28k | no data | |
Chief Financial Officer | less than a year | no data | no data | |
Chief Operating Officer | 1.3yrs | no data | no data | |
Director Corporate Communication | no data | no data | no data | |
Chief Medical Officer | 3.2yrs | no data | no data | |
Chief Business Officer | no data | no data | no data |
1.2yrs
Average Tenure
Experienced Management: 0QW5's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Member of the Supervisory Board | 19.1yrs | €24.77k | no data | |
Deputy Chairman of the Supervisory Board | 24.3yrs | €40.25k | no data | |
Chairman of Supervisory Board | 14yrs | €52.50k | no data | |
Member of the Supervisory Board | 12yrs | €27.33k | no data | |
Deputy Chairman of Supervisory Board | 8.8yrs | €35.50k | no data | |
Member of Supervisory Board | 1.9yrs | €5.08k | no data | |
Member of Supervisory Board | less than a year | no data | no data |
12.0yrs
Average Tenure
58.5yo
Average Age
Experienced Board: 0QW5's board of directors are seasoned and experienced ( 12 years average tenure).